AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01991587 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium dose of quadrivalent VLP vaccine
Description: A single medium dose of quadrivalent VLP vaccine
Study NCT01991587 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose of quadrivalent VLP vaccine
Description: A single high dose of quadrivalent VLP vaccine
Study NCT01991587 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo
Study NCT02089828 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autologous purified CD34+ cells
Study NCT02089828 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: autologous peripheral blood mononuclear cells
Study NCT03787745 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ischemic postconditioning
Description: After 60 seconds of reperfusion, ischemic postconditioning with an adequately sized balloon (60 reperfusion/60 seconds re-occlusion, four cycles) will be performed
Study NCT03787745 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional
Description: State of the art primary PCI, however thrombectomy is not allowed
Study NCT00470444 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transfusion with Red Blood Cells
Description: Units of donated Red blood cells
Study NCT00470444 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 1 unit of donated red blood cells
Description: Units of red blood cells
Study NCT00470444 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 1 unit of donated red blood cells
Description: Units of donated red blood cells
Study NCT00851045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Solution, IV, 180 mg/m2, Q14 days, Until PD
Study NCT05501418 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord mesenchymal stem cells
Description: UMSC01 cells will be IV infusion with 12 months of follow up after treatment.
Study NCT05501418 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Controlled normal saline
Description: Normal saline will be IV infusion with 12 months of follow up after treatment.
Study NCT04144413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-label Ikervis
Description: NOVA22007, IKERVIS® is a sterile, ophthalmic cationic oil-in-water emulsion containing 1mg/ml CsA.
Study NCT04144413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masked Ikervis
Description: NOVA22007, IKERVIS® is a sterile, ophthalmic cationic oil-in-water emulsion containing 1mg/ml CsA.
Study NCT04144413 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vehicle Comparator: Masked Vehicle
Description: Vehicle of IKERVIS® - sterile, ophthalmic cationic oil-in-water emulsion containing no active substance.
Study NCT00851045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil (bolus)
Description: Solution, IV, 400 mg/m2, Q14 days, Until PD
Study NCT00851045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil (infusional)
Description: Solution, IV, 2400 mg/m2, Q14 days, Until PD
Study NCT00851045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin calcium
Description: Solution, IV, 400 mg/m2, Q14 days, Until PD
Study NCT03843489 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEDLINE RENEWAL PULSE OXIMETRY SENSORS
Description: An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. Pulse oximetry monitoring is considered a standard physiological measurement and is used by clinicians in everyday situations to estimate arterial oxygen saturation. Because an arterial sample of blood is not required to make the measurement, the pulse oximeter can provide non-invasive real time information.
Study NCT03843489 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Reference CO-oximetry sensor
Description: A whole blood analyzer (CO-Oximeter) is used as the reference standard device for obtaining the functional SaO2 value from arterial blood samples obtained during the study.
Study NCT02955355 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HYQVIA
Description: Participants received HYQVIA/HyQvia SC which contains both Immune Globulin Infusion 10% (Human) (IGI, 10%) and recombinant human hyaluronidase (rHuPH20).
Study NCT00851045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT-322
Description: Solution, IV, 2 mg/kg, Q7 days, Until PD
Study NCT00851045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Solutions, IV, 5 mg/kg, Q14 days, Until PD
Study NCT00851045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab Placebo (saline solution)
Description: Solution, IV, 0 mg/kg, On day 8 of a 2-week cycle, Until PD
Study NCT00826683 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Enumeration of endothelial cell progenitor in peripheral blood by flow cytometry, Endothelial cell progenitor characterization by primary cell cultures
Study NCT00826683 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Enumeration of endothelial cell progenitor in peripheral blood by flow cytometry, Endothelial cell progenitor characterization by primary cell cultures
Study NCT04538833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: monosialic gangliosides
Description: The experimental group received 80 mg of monosialic gangliosides (GM1) on days -1, 1, and 2 of albumin-bound paclitaxel(GM1 is a single infusion).
Study NCT01260350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) capsules administered orally in a divided daily dose
Study NCT01260350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG
Description: Peginterferon alfa-2a (PEG) administered via subcutaneous injection once weekly
Study NCT01260350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV
Description: Ledipasvir (LDV) tablets administered orally once daily
Study NCT01260350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9669
Description: GS-9669 tablets administered orally once daily
Study NCT01260350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF fixed-dose combination (FDC) tablet administered once daily
Study NCT01835886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients will ascend and descend a flight of 10 steps
Description: Patients referred to pulmonary rehabilitation with documented lung disease will ascend and descend a flight of 10 steps for a period of 30 seconds
Study NCT01027000 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT01027000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Study NCT01027000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT01027000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study NCT01027000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT01027000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Study NCT01027000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Study NCT01027000 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic stem cell transplant
Study NCT04461977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: True acupuncture
Description: The selection of acupuncture points is based on Traditional Chinese Medicine (Wen, 2011) and on previous studies (Jeong,2018; Bao,2018), selected as main points: bilateral baxie, SJ5, bafeng, KID3 and ST36. Modifications or additional secondary points may be indicated according to clinical judgment throughout treatment. The needles will be inserted at a depth of 10 - 15 mm, being gently manipulated to obtain de qi sensation. The needles will be left for 20 - 25 minutes. There will be once a week acupuncture treatment, for 8 consecutive weeks. The acupuncture needles will be sterile, disposable stainless steel needles size 0.20 x 30 mm, of Korean brand Dong Bang, Chungcheongnam-do.
Study NCT04461977 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Patients will receive needling at non-acupuncture points with superficial needling without manipulation to obtain de qi, located near the real points in the hands and feet. The needles will also be left for 20 - 25 minutes. There will be once a week acupuncture treatment, for 8 consecutive weeks. There will be once a week acupuncture treatment, for 8 consecutive weeks. The acupuncture needles will be sterile, disposable stainless steel needles size 0.20 x 30 mm, of Korean brand Dong Bang, Chungcheongnam-do.
Study NCT02207920 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E Vaccine
Description: 600 mcg/mL to be administered as 1 mL intramuscular (IM) injection
Study NCT04538833 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group received placebo on days -1, 1, and 2 of albumin-bound paclitaxel (placebo as a single infusion)
Study NCT02110212 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: U/S Surgery and CCC
Description: Subjects will receive the standard of care for U/S cataract surgery and CCC to facilitate removal of the crystalline lens.
Study NCT02207920 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-HIV-PT123 Vaccine
Description: 4 mg/mL to be administered as 1 mL IM injection
Study NCT02207920 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for DNA-HIV-PT123
Description: Sodium chloride for injection USP, 0.9%; administered as 1 mL IM injection
Study NCT02207920 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for AIDSVAX B/E
Description: Sodium chloride for injection USP, 0.9%; administered as 1 mL IM injection
Study NCT02625103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: blood samples for s-clozapine and s-desmethyl-clozapine analysis are collected at 10, 11, 12, 13 and 14 hours post evening-clozapine-administration
Study NCT02625103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: Registration of the exact time of drug administration. Also postponement of any morning clozapine administration until ended blood sampling.
Study NCT04003116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen gas
Description: Supplementary oxygen during the first 48 hours added to conventional anticoagulant treatment. Patients will receive anticoagulant treatment according to updated guidelines.
Study NCT02110212 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FS Laser Surgery
Description: The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery.
Study NCT00441610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gimatecan
Study NCT03834779 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: DOORS-CHW Intervention
Description: The behavioral intervention has been developed for a collaborative CHW and re-entry program intervention that targets HIV outcomes, substance use and recidivism in HIV+ jail releasees.~Participants will be randomized to the DOORS+CHW intervention versus TAU and all participants will undergo study follow-up visits at 3, 6 and 12 months. In other words, participants randomized to the intervention arm will meet with the CHW and a staff member from DOORS. One of the primary study aims is a randomized controlled trial of an intervention which has a reasonable probability of improving the health and well-being of the subject by improving linkage to social services and the HIV clinic. The control arm will receive standard of care (referrals to case management).
Study NCT00386880 — intervention group
Intervention type: OTHER
Intervention: Sounds
Study NCT04158531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECoG sensing and stimulation
Description: Implant electrodes and a sensing+stimulation device, and use this for suppression of seizure activity
Study NCT02313467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical application of 1.5% Butenyl ALA
Study NCT03010800 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: With Yoni.Fit
Description: Abbreviated Pad Test with Yoni.Fit first, then without Yoni.Fit.
Study NCT02211599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 15% protein
Description: Meal to provide 15%en from protein.
Study NCT02211599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30% protein
Description: Meal to provide 30%en from protein.
Study NCT02211599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sweetened beverage
Description: Beverage sweetened with either sugar (sucrose) or sucralose (non-nutritive sweetener).
Study NCT03010800 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Without Yoni.Fit
Description: Abbreviated Pad Test without Yoni.Fit, then with Yoni.Fit.
Study NCT02881515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Sodium Diet
Description: Ten days of low sodium diet
Study NCT02881515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium Sodium Diet
Description: Ten days of a medium sodium diet
Study NCT02313467 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Topical application of sham control
Study NCT04184063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBMI
Description: NBMI active treatment
Study NCT04184063 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for comparison
Study NCT04501315 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood, cerebrospinal fluid and urine samples
Description: In all subjects, blood (4 mL), cerebrospinal fluid (4mL) and urine (4mL) samples were collected daily as part of the clinical routine at 6:00 AM.
Study NCT04477252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: App-core
Description: Farmalarm App of the Inmovens group - Vall d´Hebrón Hospital will be used, adapted and updated by the main researcher. The App will have the rehabilitation option where the user can consult the description of the exercise and view a demonstration video so that it can be carried out correctly at home, independently or with help. The administrator therapist of the App has the permission to create users, contact them directly through chat or video-call and personalize the exercise program.~The exercises that will be carried out in this study phase, are described in previous studies by the author Rosa Cabanas et al. All possible exercises will be included in the administration platform, and according to of each user, the prescription of some exercises or others will be made.
Study NCT04477252 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: Conventional physiotherapy is considered neuromotor development therapy as the most frequently used therapy in the management of stroke patients and in the center where the study is performed.
Study NCT00679120 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxford Uni Knee
Description: Oxford Uni Knee inserted at the time of surgery
Study NCT00679120 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxford Uni Knee
Description: Oxford Uni Knee inserted at the time of surgery (porous coated and HA coated)
Study NCT05496127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensorimotor Exercises and Yoga
Description: Within the content of sensorimotor exercise; oculomotor exercise, laser target exercise and postural stability exercise were applied. 14 yoga poses were applied within the content of Yoga Exercises.
Study NCT02234531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVER TEACHER
Description: The treatment will be performed in a darkened room, to avoid distraction provided by environmental stimuli. The patients will be seat on a standard chair in front of a wall screen handling a sensorized object with plegic hand. In case of grasping deficits the hand's surface will be used as end effector (i.e. sensorized glove worn by the patient). During the treatment a specific feedback called virtual teacher will be displayed. The Reinforced Feedback in Virtual Environment (RFVE) approach consists of performing different motor tasks moving the end effector simultaneously displayed in the virtual scenario. The Virtual Reality Rehabilitation System (VRRS®. Khymeia Group, Noventa Padovana. Italy) will be used as device to provide the artificial environment.
Study NCT02234531 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NEVER TEACHER
Description: The patients allocated to NEVER TEACHER group, will be treated using the VRRS and the proceedings will be the same as described for experimental group. In this group, the patient will move the real object (e.g. ball) following the trajectory of the corresponding virtual object displayed on the wall screen in accordance with the requested virtual task and without the 'virtual teacher' support.
Study NCT02039037 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture Group, which will hold acupuncture needles brand Dong Bang 20x15 in specific spots for the treatment of low back pain.
Study NCT02881515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Sodium Diet
Description: Ten days of a high sodium diet
Study NCT02645474 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PECS block with ropivacaine
Description: Local anesthetic (ropivacaine 0.5%, total volume 30 ml) is infiltrated in between the fasciae of serratus and minor pectoralis muscles under ultrasound guidance.
Study NCT02645474 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral block with ropivacaine
Description: Local anesthetic (ropivacaine 0.5%, total volume 20 ml) is infiltrated in the paravertebral block at T4 level under ultrasound guidance.
Study NCT02645474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Amidic local anesthetic standardly used for nerve block and infiltration
Study NCT02645474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Amidic local anesthetic standardly used for nerve block and infiltration
Study NCT02549404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK7580
Description: Oral administration
Study NCT04244552 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATRC-101
Description: ATRC-101 is an engineered, fully-human IgG1 antibody derived from a naturally-occurring human antibody.
Study NCT04244552 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (Keytruda®) is a humanized immunoglobulin G4 monoclonal antibody with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
Study NCT02039037 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroacupuncture (device 585)
Description: Electro will be added through the use of electrical stimulation to the Electro Accurate use of the device 585 at the same points Pulse.
Study NCT01250977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Study NCT01250977 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00303966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study NCT03491865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REAL media Plus curriculum
Description: REAL media Plus is a 7-level, interactive, self-paced, e-learning media literacy curriculum to prevent youth smoking and vaping use.
Study NCT01940042 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CO2 was removed by means of trandelenburg positions
Study NCT00937924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Meperidine, Midazolam
Study NCT00937924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meperidine, Midazolam
Study NCT00937924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Study NCT00937924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promethazine
Study NCT01003379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5619
Description: TC-5619-238 will be provided as hard gelatin capsules in strengths of 1mg, 5mg, and 25mg.
Study NCT01003379 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be provided with exactly the same shape, size and appearance.